iTeos Therapeutics

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapeutics to treat cancer. The company specializes in targeted immunotherapies that leverage a deep understanding of the tumor microenvironment and immunosuppressive pathways. iTeos has two clinical-stage product candidates, EOS-448 and Inupadenant, which target key mechanisms that inhibit an effective antitumor immune response. EOS-448 is an anti-TIGIT antibody designed to inhibit the immunosuppressive activity of TIGIT, while Inupadenant specifically targets A2AR, a key adenosine receptor on immune cells.

iTeos is headquartered in Watertown, MA, with a research center in Gosselies, Belgium. The company has a strong commitment to collaboration and has built a team of experts in immuno-oncology with a diverse range of experience. iTeos emphasizes a culture of scientific innovation, collaboration, and excellence, with the ultimate goal of improving the lives of people living with cancer. The company is actively pursuing partnerships with like-minded organizations and scientists to further advance its research and bring breakthrough therapies to patients.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing highly differentiated immuno-oncology therapeutics for cancer patients. They specialize in targeted immunotherapies, leveraging a deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates aimed at improving the clinical benefit of oncology therapies. Their efforts are directed at various cancer indications, utilizing their drug candidates in monotherapy, combination therapy, and intraportfolio combinations.

iTeos Therapeutics fosters a collaborative and innovative culture, emphasizing teamwork and mutual support to achieve the shared mission of developing breakthrough cancer immunotherapies. The company values scientific excellence, a commitment to corporate responsibility, and the empowerment of its employees. iTeos embraces a global mindset, with teams working together across departments, companies, and borders to bring cutting-edge therapies to patients.

iTeos Therapeutics is committed to fostering a culture of diversity, equity, and inclusion. They believe that a diverse and inclusive workforce is essential to achieving their mission of improving the lives of people with cancer. They strive to create a workplace where everyone feels valued, respected, and empowered to contribute their unique perspectives and talents. iTeos is committed to a healthy and productive workforce, diversity and inclusion, employee engagement and talent development, and reducing their environmental footprint and preserving precious resources.